The content is available as a PDF (113.4 KB).
. 2021 May 28;156:S31. doi: 10.1016/S0169-5002(21)00276-2
A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
Matt Church
, Paul Taylor
, Yvonne Summers
, Raffaele Califano
, Shereen Rafee
, Mairead Dixon
, Lisa Clarke
, Laura Cove-Smith
Matt Church
Find articles by Matt Church
Paul Taylor
Find articles by Paul Taylor
Yvonne Summers
Find articles by Yvonne Summers
Raffaele Califano
Find articles by Raffaele Califano
Shereen Rafee
Find articles by Shereen Rafee
Mairead Dixon
Find articles by Mairead Dixon
Lisa Clarke
Find articles by Lisa Clarke
Laura Cove-Smith
Find articles by Laura Cove-Smith
Issue date 2021 Jun.
Copyright © 2021 Elsevier B.V. Published by Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC8159462